Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Neuroblastoma 2Myelodysplastic Syndromes 2Multiple Myeloma 2Leukemia, Myelomonocytic, Chronic 2Breast Neoplasms 2Anemia, Refractory, with Excess of Blasts 2Wilms Tumor 1Uveal Melanoma 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1Primary Malignant Peripheral Nerve Sheath Tumors 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Oligodendroglioma 1Neoplasms, Germ Cell and Embryonal 1Neoplasm Metastasis 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Extranodal NK-T-Cell 1Leukemia, Myeloid, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Hepatoblastoma 1Gliosarcoma 1Glioma 1Glioblastoma 1GATA2 Deficiency 1Carcinoma, Lobular 1Carcinoma, Ductal, Breast 1Brain Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 23Temozolomide 22Specimen Handling 13Radiotherapy 12Biopsy 9X-Rays 8Radiation 8trametinib 6Phantoms, Imaging 6Nuclear Medicine Department, Hospital 6Bevacizumab 6larotrectinib 4erdafitinib 4dabrafenib 4abemaciclib 4ulixertinib 3palbociclib 3olaparib 3Surgical Procedures, Operative 3Nivolumab 3D2C7-(scdsFv)-PE38KDEL 3Cyclophosphamide 3tipifarnib 2tazemetostat 2selpercatinib 2pembrolizumab 2mirdametinib 2lutetium Lu 177 dotatate 2ivosidenib 2fluorodopa F 18 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioma × Vorinostat × 90 days × Clear all
NCT00268385 2026-05-07

Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas

National Cancer Institute (NCI)

Phase 1 Active not recruiting
83 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡